




Evolution diagnostic trade sales 2005-2007 (in €)



HPV: Human papillomaviruses are a group of over 100 types of viruses of which 30 are sexually transmissible. Specific high-risk HPVs are the major cause of cervical cancer, the second most common cancer in women.

HLA: Human leukocyte antigen: a set of proteins expressed on the surface of cells that allow the body to discriminate between self and non-self. Before transplantation, the process of tissue typing determines the presence and absence of these proteins to ensure that the organ donor and recipient are compatible.

LiPA or line probe assay is a DNA-based, multiparameter (ie, able to measure many items with one test) detection and identification technology that provides high value-added diagnostic information to physicians throughout therapy, enabling them to optimize the therapeutic regimen of patients.

LIA[®] or line immunoassay tests are advanced confirmatory tests allowing rapid and simultaneous detection and differentiation of multiple disease parameters, such as antibodies, in human serum or plasma samples.



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Annex to the Press Release

Consolidated Income Statement for the years ended December 31

All information in thousands EUR, except share amounts

	Years ended December 31	
	2007	2006
Product sales	50.109	47.915
Royalties	3.853	4.011
License fees	<u>164</u>	<u>1.819</u>
Revenues	54.126	53.745
<u>Cost of sales</u>	<u>(23.814)</u>	<u>(22.093)</u>
Gross profit/(loss)	30.312	31.652
Grants received for R&D	1.400	2.484
R&D contract income	2.118	1.809
<u>R&D expenses</u>	<u>(27.380)</u>	<u>(29.829)</u>
Research and development	(23.862)	(25.536)
Marketing & sales expenses	(15.250)	(15.873)
<u>Administration expenses</u>	<u>(5.806)</u>	<u>(15.963)</u>
Operating expenses	(21.056)	(31.836)
Operating profit/(loss) (EBIT)	(14.606)	(25.720)
Interest expenses	(3.498)	(1.884)
Interest income	1.086	895
<u>Investment income and other</u>	<u>(190)</u>	<u>1.736</u>
Other income/(expenses)	(2.602)	747
Profit/(loss) before taxes	(17.208)	(24.973)
Income taxes – (payable)/adjustment	(169)	(84)
Net profit/(loss) for the year attributable to the equity holders of the Company	<u>(17.377)</u>	<u>(25.057)</u>
Operating profit/(loss) before depreciation and amortization (EBITDA)	(3.634)	(16.758)
EPS from continuing operations (basic/diluted)	(0.56)	(0.81)
Shares used in computing per share amount - basic/diluted	30.878.920	30.878.967



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Consolidated Balance Sheet

	Years ended December 31	
	2007	2006
ASSETS		
Current assets		
Cash and cash equivalents	23.478	22.349
Accounts receivable	19.060	19.051
Inventories	10.210	7.179
<u>Other accounts receivable</u>	<u>1.621</u>	<u>1.058</u>
Total current assets	54.369	49.637
Non current assets		
Intangible assets	30.597	33.277
Property, plant and equipment	19.600	22.518
<u>Accounts receivable more than one year</u>	<u>359</u>	<u>152</u>
Total non current assets	50.556	55.947
TOTAL ASSETS	104.925	105.584
LIABILITIES & SHAREHOLDERS' EQUITY		
Current liabilities		
Current installments of long-term obligations	9.932	8.690
Notes payable to bank	-	2.396
Trade accounts payable	8.798	7.564
Other current liabilities	14.579	15.167
<u>Current tax liabilities</u>	<u>187</u>	<u>230</u>
Total current liabilities	33.496	34.047
Non current liabilities		
Long-term obligations	41.039	22.543
Provisions	762	6.950
<u>Other non current liabilities</u>	<u>1.677</u>	<u>1.722</u>
Total non current liabilities	43.478	31.215
Shareholders' equity		
Share capital	19.398	19.398
Issuance premium	163.070	157.419
Reserves	(1.501)	(856)
<u>Retained earnings</u>	<u>(153.016)</u>	<u>(135.639)</u>
Total shareholders' equity	27.951	40.322
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	104.925	105.584



Consolidated Statement of Shareholders' Equity

	Number of shares issued	Equity attributable to the equity holders of the Company				
		Share capital	Issuance premium	Retained earnings	Accumulated currency translation and fair value adjustments	TOTAL shareholders' equity
Total as per December 31, 2005	30.878.479	19.398	156.890	(110.582)	94	65.800
Issuance of shares	441	-	(15)	-	-	(15)
Currency translation adjustment	-	-	-	-	(950)	(950)
Net profit/(loss)	-	-	-	(25.057)	-	(25.057)
Share-based payment	-	-	544	-	-	544
Total as per December 31, 2006	30.878.920	19.398	157.419	(135.639)	(856)	40.322
Currency translation adjustment	-	-	-	-	(645)	(645)
Net profit/(loss)	-	-	-	(17.377)	-	(17.377)
Recognition of share-based payment	-	-	130	-	-	130
Recognition of equity component of convertible bond	-	-	5.521	-	-	5.521
Total as per December 31, 2007	30.878.920	19.398	163.070	(153.016)	(1.501)	27.951



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Consolidated Statement of Cash Flows

	Years ended December 31	
	2007	2006
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit/(loss)	(17.377)	(25.057)
Depreciation, amortization and impairment results	10.975	8.962
Increase/(decrease) in provisions	(6.187)	244
Share- based payment	131	544
Gain on disposal of fixed assets	(14)	(18)
Loss on disposal of fixed assets	545	252
Interest paid	3.498	1.753
Interest received	(1.007)	(886)
(Increase)/decrease in accounts receivable	(778)	(2.584)
(Increase)/decrease in inventories	(3.031)	(530)
Increase/(decrease) in accounts payable	1.234	(145)
Increase/(decrease) in accruals and other liabilities	(3.079)	(3.348)
Increase/(decrease) in current tax liabilities	(43)	208
Increase/(decrease) in non current liabilities	(42)	126
Total adjustments	2.202	4.578
Net cash used in operating activities	(15.175)	(20.479)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(2.819)	(3.369)
Purchase of intangible	(3.093)	(2.944)
Net cash used in investing activities	(5.912)	(6.313)



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Consolidated Statement of Cash Flows (Continued)

	Years ended December 31	
	2007	2006
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on long-term obligations	(8.905)	(8.848)
Proceeds from long-term obligations	3.500	935
Payments on notes payable to bank	(2.396)	(1.202)
Proceeds from notes payable to bank	-	2.882
Currency translation adjustment	(647)	(950)
Proceeds from issuance of common stock	-	(16)
Proceeds from issuance of convertible bond	31.700	-
Transaction costs	(1.036)	-
Net cash provided by/(used in) financing activities	22.216	(7.199)
Net increase/(decrease) in cash and cash equivalents	1.129	(33.991)
Cash and cash equivalents at beginning of year	22.349	56.340
Cash and cash equivalents at end of year	23.478	22.349



INNOGENETICS
BIOTECHNOLOGY FOR HEALTHCARE

**Segment Information
for the years ended December 31**

	Diagnostics		Therapeutics		Total	
	2007	2006	2007	2006	2007	2006
Revenues	50.922	51.557	3.204	2.188	54.126	53.745
Gross profit	29.999	31.403	313	249	30.312	31.652
Research & Development income	1.097	1.292	2.421	3.001	3.518	4.293
<u>Research & Development expenses</u>	<u>(13.799)</u>	<u>(13.515)</u>	<u>(13.581)</u>	<u>(16.314)</u>	<u>(27.380)</u>	<u>(29.829)</u>
Research & Development	(12.702)	(12.223)	(11.160)	(13.313)	(23.862)	(25.536)
Operating expenses	(17.186)	(28.231)	(3.870)	(3.605)	(21.056)	(31.836)
Operating profit/(loss) before depreciation and amortization (EBITDA)	6.983	(2.792)	(10.617)	(13.966)	(3.634)	(16.758)
Operating profit/(loss) (EBIT)	111	(9.051)	(14.717)	(16.669)	(14.606)	(25.720)